DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR EMTRICITABINE

« Back to Dashboard

Clinical Trials for Emtricitabine

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00002362	A Comparison of Emtricitabine and Abacavir Used in a Three-Drug Combination in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs	Suspended	Triangle Pharmaceuticals	Phase 3	This study will look at whether emtricitabine is as safe and effective as abacavir (ABC) when taken with stavudine (d4T) and efavirenz (EFV) in patients who have never taken anti-HIV drugs.
NCT00006144	A Study of HIV-Disease Development in Aging	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	The purpose of this study is to better understand the relationship between age and HIV disease progression. This study will explore the possible relationship between age and HIV disease progression. Older age is an important risk factor for faster disease development, but older people may respond better to combination drug therapy. This relationship needs to be understood better.
NCT00006208	A Comparison of Emtricitabine and Stavudine Used With Didanosine Plus Efavirenz in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs	Unknown status	Triangle Pharmaceuticals	Phase 3	The purpose of this study is to compare the safety and effectiveness of emtricitabine and stavudine when given with didanosine plus efavirenz to HIV-infected patients.
NCT00016718	Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 1/Phase 2	Treatment of HIV-infected patients involves combining drugs from different classes of anti-HIV drugs. One preferred regimen for adults is 2 nucleoside reverse transcriptase inhibitors (NRTIs) and 1 protease inhibitor (PI). For children, this regimen may be too complicated or the drugs may be too difficult to take by mouth. The purpose of this study is to determine the long-term safety and effectiveness of daily didanosine (ddI), efavirenz (EFV), and emtricitabine (FTC) in pediatric patients who have taken few or no anti-HIV drugs.

Clinical Trial Conditions for Emtricitabine

Condition Name

Condition Name for Emtricitabine
Intervention	Trials
HIV Infections	132
HIV	82
HIV-1 Infection	38
HIV Infection	32

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Emtricitabine
Intervention	Trials
HIV Infections	208
Acquired Immunodeficiency Syndrome	78
Immunologic Deficiency Syndromes	46
Infection	46

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Emtricitabine

Trials by Country

Trials by Country for Emtricitabine
Location	Trials
Canada	133
United Kingdom	84
Spain	78
Germany	73
France	72

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Emtricitabine
Location	Trials
California	117
Florida	100
Texas	91
New York	88
North Carolina	83

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Emtricitabine

Clinical Trial Phase

Clinical Trial Phase for Emtricitabine
Clinical Trial Phase	Trials
Phase 4	119
Phase 3	104
Phase 2/Phase 3	16

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Emtricitabine
Clinical Trial Phase	Trials
Completed	197
Recruiting	57
Active, not recruiting	55

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Emtricitabine

Sponsor Name

Sponsor Name for Emtricitabine
Sponsor	Trials
Gilead Sciences	123
National Institute of Allergy and Infectious Diseases (NIAID)	51
Merck Sharp & Dohme Corp.	30

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Emtricitabine
Sponsor	Trials
Other	371
Industry	290
NIH	70

Export unavailable in trial.
Subscribe for complete access.